Asceneuron
Asceneuron researches and develops oral small molecule therapeutics targeting tauopathies for treating progressive supranuclear palsy (PSP), other related neurodegenerative diseases and Alzheimer’s disease. The lead product, an O-GlcNAcase inhibitor that in preclinical studies has been demonstrated to modulate tau pathology, has entered the critical regulatory studies to allow its entry into human clinical testing. Neuronal deposits of the microtubule-associated tau protein are a common feature of tauopathies and known to be a major contributor to neurodegenerative diseases.
Sector
Biopharmaceuticals
Strategies
Capital
Status
Active
Website
www.asceneuron.com
Related Articles
Asceneuron awarded second grant from The Michael J. Fox Foundation for accelerated research into novel Parkinson’s disease therapies
Asceneuron appoints Peter Van Vlasselaer as Chairman
Asceneuron appoints J. Michael Ryan, M.D. as Chief Medical Officer
Asceneuron Receives Grant from The Michael J. Fox Foundation for Parkinson’s Research
Asceneuron raises CHF 30 million in a Series A financing round led by Sofinnova Partners
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.